CNBC International’s Tanvir Gill and Nancy Hungerford interact with Umang Vohra to discuss the company’s performance, play in COVID-19 and future outlook and plans. Umang talks about how only 5% of the company’s sales come from Remdesivir and the COVID related portfolio, and that the company is also doing incredibly well beyond the COVID portfolio. The conversation highlights how Cipla is the No. 2 seller of respiratory devices across the world and is seeing very strong momentum in the lung therapy as lung leaders of the world, as well as in other therapies.

Source credit: Interview appeared on CNBC International's Street Signs Asia show

We have launched the third chapter of the campaign to dispel myths about asthma and normalize the use of inhalers.

News: Cipla announced a INR 25 crore fund to support the Indian Government’s efforts to effectively combat the COVID-19 pandemic. This includes a voluntary donation of approximately INR 3 crore from Cipla employees who have stepped forward in this hour of national need. Through its wide-ranging relief efforts, the Company is focusing on initiatives that have the maximum impact and reach. It is currently supporting public health institutions, frontline healthcare workers, vulnerable patients and communities struggling in the aftermath.

News: Mumbai-based drug major Cipla, credited with several innovations especially in respiratory and flu therapy, could well become one of the first domestic companies to roll out new drugs for the coronavirus. The company is both fast-tracking development of these drugs with government laboratories, and repurposing its wide portfolio of respiratory, asthma, anti-virals and HIV drugs to meet challenges arising from Covid-19 in India.

Structural changes in the global pharma industry are throwing up challenges and opportunities. Enter Cipla with its expertise in medicine, and vision for relevance beyond pharma.